详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine,Shanghai Jiao Tong University, Shanghai, China [2]Department of Thoracic MedicalOncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya Schoolof Medicine, Central South University, Changsha, China [3]Department of Oncology,Jilin Cancer Hospital, Changchun, China [4]Department of Respiratory Medicine, HenanCancer Hospital, Zhengzhou, China [5]Department of Thoracic Medical Oncology,Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, China [6]Departmentof Thoracic Medical Oncology, Hubei Cancer Hospital, Wuhan, China [7]Departmentof Oncology, Xuzhou Central Hospital, Xuzhou, China [8]Department of Oncology,Jinan Central Hospital affiliated to Shandong University, Jinan, China [9]Department ofRespiratory Medicine, Nanjing University Medical School affiliated Nanjing DrumTower Hospital, Nanjing, China [10]Department of Respiratory Medicine, Hebei MedicalUniversity Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang,China [11]Department of Oncology, The First Hospital of Jilin University,Changchun, China [12]Department of Respiratory Medicine, West China Hospital ofSichuan University, Chengdu, China [13]Department of Oncology, Beijing Chest Hospital,Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing, China [14]Oncology Department, The First Affiliated Hospital of ZhengzhouUniversity, Zhengzhou, China [15]Department of Oncology, The First Affiliated Hospitalof Xiamen University, Xiamen, China [16]Department of Oncology, The Second AffiliatedHospital of Nanchang University, Nanchang, China [17]Oncology Department, AnhuiProvincial Hospital, Hefei, China [18]Department of Oncology, Henan Provincial People’sHospital, Zhengzhou, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 56.7 最新[2023版] 38.2 最新五年平均 50.5 出版当年[2022版] 32.4 出版当年五年平均 51.769 出版前一年[2021版] 56.7 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine,Shanghai Jiao Tong University, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：